LPL Financial
TCRX icon

LPL Financial’s TScan Therapeutics TCRX Stock Holding History

LPL Financial’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.7K Hold
22,500
– – ﹤0.01% 5864
2025
Q4 		$22.5K Buy
22,500
+1,000
+5% +$1.45K ﹤0.01% 5801
2025
Q3 		$39.1K Buy
+21,500
New +$38.1K ﹤0.01% 5663
2023
Q2 		– Sell
-12,000
Closed -$25.2K – 4681
2023
Q1 		$25.2K Sell
12,000
-5,000
-29% -$11.9K ﹤0.01% 4387
2022
Q4 		$26.4K Buy
17,000
+2,000
+13% +$4.91K ﹤0.01% 4339
2022
Q3 		$46K Sell
15,000
-1,000
-6% -$3.28K ﹤0.01% 4242
2022
Q2 		$50K Buy
+16,000
New +$43.8K ﹤0.01% 4235
2022
Q1 		– Sell
-13,000
Closed -$59K – 4384
2021
Q4 		$59K Buy
+13,000
New +$93.9K ﹤0.01% 4214

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

LPL Financial's TCRX Position: Q1 2026 in Review

LPL Financial held its TScan Therapeutics (TCRX) position steady in Q1 2026 at 22,500 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5864.

LPL Financial first reported a position in TCRX in Q4 2021 and has held it in 8 quarters since. The position peaked at $59K in Q4 2021. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • LPL Financial held 22,500 shares of TScan Therapeutics worth $22.7K as of Q1 2026.
  • LPL Financial left its TScan Therapeutics share count unchanged in Q1 2026.
  • TScan Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5864 holding.
  • LPL Financial first reported a position in TScan Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • LPL Financial's TScan Therapeutics position peaked at $59K in Q4 2021.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.